Αρχική World News Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other Cancers

Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other Cancers

September 4, 2018, by NCI Staff

A model representing the crystal structure of arsenic (red and yellow spheres) interacting with and inhibiting the activity of the Pin1 protein (red, white, and blue).

Nature Communications Aug 2018 doi: 10.1038/s41467-018-05402-2. CC BY 4.0.

A two-drug combination commonly used to treat a type of leukemia blocks an enzyme that has a central role in breast and many other cancers, a new study has found.

The drug combination, arsenic trioxide (Trisenox) and tretinoin (also known as retinoic acid), has essentially turned acute promyelocytic leukemia (APL) from a fatal disease into a curable one. But the mechanism by which it kills cancer cells has been a mystery.

In an earlier study, Kun Ping Lu, M.D., Ph.D., and Xiao Zhen Zhou, M.D., of Beth Israel Deaconess Medical Center, in Boston, and their colleagues found that retinoic acid inhibits the key enzyme, Pin1. Now, they’ve found that arsenic also blocks Pin1, and the combination of the two drugs inhibits the enzyme more effectively than either drug alone.

Pin1 is considered a cancer master regulator—a protein that regulates entire cellular networks that are critical to cancer progression. Some scientists consider master regulators ideal drug targets.

The findings are “an interesting launching pad for further investigation,” said Joanna Watson, Ph.D., of NCI’s Division of Cancer Biology, which helped fund the study.

The combination treatment slowed the growth of several different laboratory models of breast cancer, the researchers reported. Their findings, published August 9 in Nature Communications, provide the rationale to test the drug combination in a clinical trial of women with breast cancer, said Dr. Lu.

Pin1: An Ideal Drug Target

Pin1 switches the shape of the amino acid proline within proteins. This conformation change can activate 40 proteins that promote tumor growth and inactivate more than 20 proteins that suppress tumor growth.

Pin1 is overactive in many different types of cancer, including breast, lung, prostate, and colon cancer. It is also found at higher than normal levels in breast cancer stem cells—specialized cancer cells that are thought to be responsible for tumor initiation, growth, metastasis, and drug resistance.

On the other hand, mice that lack Pin1 are protected from developing cancer even in the presence of cancer-causing mutations in other genes.

Because arsenic is often combined with retinoic acid to treat APL, the researchers wanted to know if arsenic also targets Pin1. But rather than studying APL, they focused on triple-negative breast cancer because this aggressive disease has a poor prognosis and is not effectively treated with targeted therapies.

Arsenic and Retinoic Acid Work Together           

First, the researchers found that arsenic inhibited Pin1 activity, which in turn slowed the growth of triple-negative breast cancer cells. They then showed that arsenic needed to bind to Pin1 to impede breast cancer cell growth. Interacting with arsenic makes Pin1 unstable, explained Dr. Lu, and as a result, the protein is destroyed.

Arsenic also lowered Pin1 levels and slowed the growth of breast cancer xenograft tumors in mice.

Next, the researchers examined the effects of combining arsenic and retinoic acid in cell and mouse models of triple-negative breast cancer.

Treating cells or mice with arsenic or retinoic acid alone lowered Pin1 levels and slowed cell growth. But the combination of the two drugs had an even greater effect. The combination also prevented Pin1 from altering the levels of certain proteins that control cancer growth, producing effects that are similar to those of inactivating the Pin1 gene in breast cancer cells.

The combination showed synergy, meaning that the resulting effect “is above and beyond what you would expect by just adding the two [drugs] together,” explained Dr. Watson.

Synergy may reflect the fact that, in APL cells, retinoic acid treatment raises the level of a transporter that brings arsenic inside of cells. Levels of the transporter also increased when Dr. Lu and his colleagues treated triple-negative breast cancer cells with retinoic acid. By contrast, arsenic and retinoic acid did not act synergistically in triple-negative breast cancer cells engineered to lack this transporter.

These results suggest that, in addition to inhibiting Pin1 directly, retinoic acid increases the amount of arsenic in cells by boosting the level of this transporter, Dr. Lu explained. The arsenic then further inhibits Pin1.

He added, this also implies that when used in combination with retinoic acid, a lower concentration of arsenic could achieve the desired effect—potentially reducing the side effects of arsenic, which is extremely toxic at high doses.

Targeting Breast Cancer Stem Cells

Developing drugs that effectively target cancer stem cells has proven to be a challenge, and cancer stem cells that remain after treatment are thought to be a cause of cancer relapse and metastasis.

Dr. Lu’s team found that, to a greater extent than either drug alone, the combination of arsenic and retinoic acid eliminated triple-negative breast cancer stem cells. The effects of the combination treatment were similar to those of inactivating the Pin1 gene in breast cancer cells, they found.

The researchers also found that the combination of arsenic and retinoic acid eliminated cancer stem cells that were resistant to chemotherapy, and it eliminated cancer stem cells in mouse models of triple negative breast cancer.

New Insights and Potential New Therapy

It had long been thought that arsenic’s main target was a fusion protein that is found only in APL, and there were doubts that the drug would be effective against other types of cancer, despite some evidence of activity. In their earlier study, Drs. Lu and Zhou and their colleagues found that retinoic acid targets this fusion protein by inhibiting Pin1.

“Identifying Pin1 as the major target of arsenic will hopefully stimulate clinical trials for other [types of] cancer,” Dr. Lu said.

The researchers hope to develop a clinical trial to combine arsenic with the standard therapy for women with triple-negative breast cancer. And because their findings show that arsenic’s activity depends on the expression of Pin1 and its transporter, Dr. Lu said they want to select patients whose cancers express both proteins.

As for retinoic acid, it is normally broken down quickly inside the human body. To enhance its ability to reach solid tumors, the team is interested in developing a more stable form of retinoic acid. If such a form can be created, it could potentially be combined with arsenic in clinical trials, Dr. Lu said.

Another advantage of having learned one mechanism of arsenic’s anticancer activity, said Dr. Watson, is being able to develop new drugs that potentially target Pin1 more efficiently and with fewer side effects than arsenic itself. The research team is also working to develop a targeted drug that blocks Pin1 activity.

Dr. Lu noted that because Pin1 controls multiple pathways that contribute to cancer development, cancer cells might be less able to develop resistance to drugs that block Pin1’s activity—something that often occurs with targeted therapies that attack a single pathway.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women Under 40

U.S. breast cancer death rates decreased by about 1% per year between 2013 and 2018. What were the new case rates during that same...

Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers

A large, observational, registry-based study that leveraged systematically collected data gathered both retrospectively and prospectively through the International Replication Repair Deficiency Consortium reveals impressive...

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...